Catalysts for Genentech Inc
166 tracked
Dec 10, 2024
approval
ACTEMRA (TOCILIZUMAB) — FDA approval
tocilizumab
→
Dec 10, 2024
approval
ACTEMRA (TOCILIZUMAB) — FDA approval
tocilizumab
→
Nov 22, 2024
approval
LUNSUMIO (MOSUNETUZUMAB-AXGB) — FDA approval
mosunetuzumab
→
Oct 10, 2024
approval
ITOVEBI (INAVOLISIB) — FDA approval
inavolisib
→
Sep 20, 2024
approval
ACTEMRA (TOCILIZUMAB) — FDA approval
tocilizumab
→
Sep 20, 2024
approval
ACTEMRA (TOCILIZUMAB) — FDA approval
tocilizumab
→
Sep 19, 2024
approval
ACTEMRA (TOCILIZUMAB) — FDA approval
tocilizumab
→
Sep 19, 2024
approval
ACTEMRA (TOCILIZUMAB) — FDA approval
tocilizumab
→
Sep 17, 2024
approval
EVRYSDI (RISDIPLAM) — FDA approval
EVRYSDI
→
Sep 12, 2024
approval
TECENTRIQ HYBREZA (ATEZOLIZUMAB AND HYALURONIDASE-TQJS) — FDA approval
(atezolizumab + hyaluronidase (human recombinant))
→
Jul 3, 2024
approval
VABYSMO (FARICIMAB-SVOA) — FDA approval
faricimab
→
Apr 22, 2024
approval
TECENTRIQ (ATEZOLIZUMAB) — FDA approval
atezolizumab
→
Feb 29, 2024
approval
EVRYSDI (RISDIPLAM) — FDA approval
EVRYSDI
→
Oct 26, 2023
approval
VABYSMO (FARICIMAB-SVOA) — FDA approval
faricimab
→
Oct 3, 2023
approval
EVRYSDI (RISDIPLAM) — FDA approval
EVRYSDI
→
Jun 15, 2023
approval
COLUMVI (GLOFITAMAB-GXBM) — FDA approval
glofitamab
→
May 12, 2023
approval
TECENTRIQ (ATEZOLIZUMAB) — FDA approval
atezolizumab
→
May 12, 2023
approval
TECENTRIQ (ATEZOLIZUMAB) — FDA approval
atezolizumab
→
Apr 19, 2023
approval
POLIVY (POLATUZUMAB VEDOTIN-PIIQ) — FDA approval
polatuzumab vedotin
→
Mar 24, 2023
approval
EVRYSDI (RISDIPLAM) — FDA approval
EVRYSDI
→
Jan 27, 2023
approval
VABYSMO (FARICIMAB-SVOA) — FDA approval
faricimab
→
Dec 22, 2022
approval
LUNSUMIO (MOSUNETUZUMAB-AXGB) — FDA approval
mosunetuzumab
→
Dec 21, 2022
approval
ACTEMRA (TOCILIZUMAB) — FDA approval
tocilizumab
→
Dec 21, 2022
approval
ACTEMRA (TOCILIZUMAB) — FDA approval
tocilizumab
→
Dec 9, 2022
approval
TECENTRIQ (ATEZOLIZUMAB) — FDA approval
atezolizumab
→
Dec 2, 2022
approval
TECENTRIQ (ATEZOLIZUMAB) — FDA approval
atezolizumab
→
Sep 21, 2022
approval
EVRYSDI (RISDIPLAM) — FDA approval
EVRYSDI
→
Jul 27, 2022
approval
GAZYVA (OBINUTUZUMAB) — FDA approval
obinutuzumab
→
Jul 12, 2022
approval
GAZYVA (OBINUTUZUMAB) — FDA approval
obinutuzumab
→
May 27, 2022
approval
EVRYSDI (RISDIPLAM) — FDA approval
EVRYSDI
→